Pharmacokinetics and Pharmacodynamics of Oral Sertraline Before and After Bariatric Surgery
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anxiety Disorders
- Depression
- Overweight
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
The pharmacokinetic changes of sertraline after bariatric surgery are studied by assessing the exposition for sertraline in individuals with long term treatment by measuring the area under the curve (AUC0-?) 8 weeks before and one, six and twelve months after bariatric surgery in 30 participants. Th...
The pharmacokinetic changes of sertraline after bariatric surgery are studied by assessing the exposition for sertraline in individuals with long term treatment by measuring the area under the curve (AUC0-?) 8 weeks before and one, six and twelve months after bariatric surgery in 30 participants. The effect of variation of sertraline concentration is studied by a psychiatric assessment of depressive symptoms and symptoms of anxiety disorder. The aim ist to study if there is a relation between changes in pharmacokinetics and effect of sertraline after bariatric surgery. For the assessment of side effects a self-reporting scale is used. These participants are recruited consequentially with the aim to get equal numbers of patients with both most usual types of surgery in Sweden (laparoscopic RYGB and gastric sleeve).
Tracking Information
- NCT #
- NCT04147000
- Collaborators
- Örebro University, Sweden
- Investigators
- Principal Investigator: Michael Andresen, MD Linkoping university, Örebro university Study Director: Ylva Böttiger, Professor Linkoeping University
Get Well Soon